Ascentage Pharma Group International (NASDAQ:AAPG) Sees Unusually-High Trading Volume – Should You Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw strong trading volume on Friday . 3,938 shares changed hands during trading, a decline of 13% from the previous session’s volume of 4,552 shares.The stock last traded at $17.6950 and had previously closed at $17.11.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft assumed coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 target price on the stock. B. Riley Financial assumed coverage on Ascentage Pharma Group International in a research report on Wednesday. They set a “buy” rating and a $45.00 target price on the stock. China Intl Cap raised Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. BTIG Research reaffirmed a “buy” rating and set a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Monday, April 13th. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday. Two analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $46.43.

Ascentage Pharma Group International Price Performance

The business’s fifty day simple moving average is $22.10 and its 200 day simple moving average is $24.75. The company has a quick ratio of 1.77, a current ratio of 1.79 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The firm had revenue of $24.72 million for the quarter. On average, analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -0.96 earnings per share for the current fiscal year.

Institutional Trading of Ascentage Pharma Group International

Several hedge funds have recently made changes to their positions in AAPG. XY Capital Ltd lifted its holdings in shares of Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the last quarter. UBS Group AG lifted its holdings in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International in the 2nd quarter worth approximately $391,000. Finally, Citadel Advisors LLC bought a new stake in shares of Ascentage Pharma Group International in the 3rd quarter worth approximately $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.